Also found in: Wikipedia.
TEVATutmonda Esperantista Vegetarana Asocio (Esperanto; vegetarian association)
TEVAThreat Ensemble Vulnerability Assessment (US EPA)
TEVATropical Everglades Visitor Association (Florida City, FL)
TEVATennessee Virtual Archives (Nashville, TN)
TEVATucson Electric Vehicle Association
References in periodicals archive ?
Teva is currently in patent litigation concerning this product in the U.
market exclusivity for generic products, the impact of consolidation of our distributors and customers, regulatory changes that may prevent Teva from utilizing exclusivity periods, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra[R], Neurontin[R] and Wellbutrin XL[R] , the effects of competition on our innovative products, especially Copaxone[R] sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.
Food and Drug Administration approval of IMPAX's Bupropion Hydrochloride Extended-Release Tablets, 300 mg and for Teva to sell the product within Anchen's 180-day exclusivity.
We believe that accessing Protalix's plant cell culture platform will provide Teva with various advantages, including IP advantages and reduced cost of goods," said Amir Elstein, Group Vice President - Global Specialty Pharmaceutical Products of Teva Pharmaceutical Industries Ltd.
Teva is an excellent partner for maximizing the commercialization of Protalix's protein development capabilities.
We believe that accessing the Procognia technology will provide Teva with a distinct competitive advantage," said Amir Elstein, Group Vice President - Global Specialty Pharmaceutical Products of Teva Pharmaceutical Industries Ltd.
The study results with once daily oral laquinimod are very encouraging and further demonstrate our ongoing commitment to developing new classes of therapies for MS, including oral therapies, to treat the disease, as well as to improve the patients' quality of life", said Israel Makov, President and CEO of Teva Pharmaceutical Industries Ltd.
Teva will work closely with employees and local authorities to ensure as seamless a transition as possible and to offer financial and placement assistance to those staff affected by the closure.
The development of AZILECT(R) is part of a long-term alliance for co-development in Parkinson's disease and European marketing between Teva and H.